Discussing Lung Cancer ASCO 2023 Highlights
Focusing on practice changing studies with Dr. Charu Aggarwal, Director, Precision Oncology Innovation, Associate Professor of Lung Cancer Excellence at Penn Medicine. Covering three important studies
August 24, 2024
Key Points
ADAURA trial update with increase OS with adjuvant Osimertinib
KEYNOTE 789 – Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutant
KEYNOTE 671 – Randomized, double-blind, phase 3 study of pembrolizumab or placebo plus platinum-based chemotherapy followed by resection and pembrolizumab or placebo for early stage NSCLC
Tags:
Related Posts
ConferencesWCLC2025ArticlesSeptember 18, 2025
WCLC 2025 Highlights: FLAURA2, HARMONi, ALCHEMIST with Dr. Balazs Halmos
ConferencesASCO2025July 31, 2025